ESMO 2023
Oct 20 - Oct 24, 2023
|
Madrid, Spain / Virtual (Hybrid)
Medical Material
-
evERA Breast Cancer:
A study of giredestrant + everolimus
versus physician’s choice of endocrine therapy + everolimus
in patients with ER-positive, HER2-negative LA/mBC -
INAVO121:
A study of inavolisib + fulvestrant versus
alpelisib + fulvestrant in patients with PIK3CAmut,
HR+/HER2– LA/mBC in a post-CDK4/6i setting
-
INAVO122:
A study of inavolisib + PH FDC SC in
patients with PIK3CA-mutated, HER2+ locally
advanced or metastatic breast cancer -
INAVO120:
A study of inavolisib + palbociclib
+ fulvestrant in patients with PIK3CA-mutated,
HR-positive, HER2-negative LA/mBC -
CO44194:
A randomized Phase II study of tobemstomig (Anti-PD1-LAG3 Antibody)+ nab-paclitaxel compared with pembrolizumab + nab-paclitaxel in participants with previously untreated, PD-L1-positive, locally-advanced unresectable or metastatic TNBC
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.